The biology behind the disease explains why the new drugs work the way they do. Transthyretin is a transport protein produced almost entirely in the liver, circulating in the blood as a four-part tetramer that carries thyroxine and retinol-binding protein. In ATTR amyloidosis, the tetramer dissociates into individual subunits that misfold and aggregate into insoluble fibrils that deposit in the myocardium. Dissociation of the tetramer is the rate-limiting step of this amyloidogenic cascade, which is precisely where the first drug class intervenes. Tafamidis, approved in Germany in 2020, and acoramidis, approved in 2025, are so-called kinetic stabilizers that selectively bind to the unoccupied thyroid hormone-binding site of the tetramer, locking it shut and preventing the misfolding that leads to amyloid deposition.

The second class attacks the problem upstream. Vutrisiran, a small interfering RNA approved for ATTR-CM in 2025, is a double-stranded RNA molecule conjugated to a sugar that escorts it into liver cells, where it binds the messenger RNA encoding transthyretin and triggers its degradation. The result is a marked, durable reduction in hepatic production of the precursor protein, with a mean maximum TTR reduction of 57 to 97 percent sustained for at least 90 days after each subcutaneous injection. Rather than stabilizing the protein that already exists, vutrisiran essentially shuts down the factory, and clinical outcomes in the phase 3 HELIOS-B trial now document what that pharmacologic logic delivers in patients.

The evidence base for all three drugs rests on landmark randomized trials, each with its own design and population. For tafamidis, the pivotal ATTR-ACT trial randomized 441 patients, predominantly older men with the wild-type form of the disease, to drug or placebo on top of standard heart failure therapy. Over 30 months, tafamidis significantly reduced the hierarchical composite of all-cause mortality and cardiovascular hospitalization, with an absolute mortality reduction of 13.4 percent and a strikingly low number needed to treat of eight. Long-term extension analyses confirmed a sustained survival benefit beyond five years for patients who started tafamidis early, compared to those who began therapy only after the trial ended. That pattern, in which delayed treatment never fully caught up, has become the most consistent lesson across the entire field.

Acoramidis, designed to mimic the super-stabilizing T119M transthyretin variant, produced one of the most compelling results in the ATTRibute-CM trial. In a modified intention-to-treat population of 611 patients followed for 30 months, acoramidis achieved a win ratio of 1.8 on a hierarchical endpoint combining mortality, cardiovascular hospitalizations, NT-proBNP change and six-minute walk distance. Although the mortality effect alone did not reach statistical significance at 30 months, it did so after 42 months in the open-label extension, with a hazard ratio of 0.64. Notably, treatment with acoramidis raised serum TTR levels early, and each 5 milligrams per deciliter increase in TTR was associated with a 31.6 percent reduction in the risk of all-cause mortality, an observation the panel considers an important pharmacodynamic signal for monitoring therapy.

Vutrisiran’s HELIOS-B trial extended the gene-silencing approach to the cardiomyopathy population with equally impressive results. Over approximately 33 months, vutrisiran reduced the composite of all-cause mortality and recurrent cardiovascular events by 25 to 30 percent in relative terms, and cut all-cause mortality by roughly one third at 42 months. Patients on vutrisiran preserved walking distance, experienced attenuated rises in NT-proBNP detectable as early as six months, and maintained quality of life scores that placebo patients lost. The benefits were most pronounced in patients on monotherapy and in those with less advanced disease, reinforcing the same theme: intervene early, because amyloid burden accumulated before treatment may never be fully recovered.

Given the absence of any head-to-head trial between the three agents, the panel’s central conclusion is deliberately cautious: based on current scientific data, tafamidis, acoramidis and vutrisiran are considered similarly effective for most patients with confirmed ATTR-CM. All three demonstrated significant reductions in all-cause mortality and cardiovascular hospitalizations in their respective phase 3 studies, with comparable tolerability profiles. The one clear exception concerns patients with hereditary ATTR-CM and a mixed phenotype, meaning concurrent cardiomyopathy and polyneuropathy, for whom the panel recommends vutrisiran as first-line therapy, based on its demonstrated efficacy against both cardiac and neurological manifestations in the HELIOS-A and HELIOS-B programs.

Safety data, while reassuring for all three agents, differ in the details that matter for individual patients. Tafamidis is generally well tolerated, with mild gastrointestinal symptoms such as diarrhea and constipation as the most frequent complaints, and a permanent discontinuation rate of only 0.8 percent in the pivotal trial. Acoramidis also showed a favorable profile, though mild to moderate gastrointestinal effects including diarrhea, nausea and dyspepsia occurred more frequently than with placebo, and gout was observed more often in treated patients. An early, reversible rise in serum creatinine was noted, but renal pharmacokinetics were not meaningfully affected and no dose adjustment is required. Vutrisiran, administered subcutaneously every three months, showed a safety profile comparable to placebo across age groups, with transient injection-site reactions in about 2 percent of patients, though patients require daily vitamin A supplementation of 2500 international units, typically at their own expense in Germany, because gene silencing also reduces this essential nutrient’s transport protein.

The consensus document goes well beyond pharmacology, addressing the practical realities that determine whether patients actually receive treatment. Annual therapy costs in Germany currently range from approximately 100,000 to 150,000 euros per patient, a figure that fell after a 50 percent price reduction for vutrisiran at the end of 2025 but still raises serious cost-effectiveness concerns, given that the median age at diagnosis is around 80 years. The authors note that prescribing is almost exclusively concentrated in specialized amyloidosis centers, creating bottlenecks that delay diagnosis and treatment and worsen prognosis. To counter this, the panel proposes a shared care model in which centers establish the diagnosis and initiate therapy, while trained office-based physicians handle routine monitoring and ongoing prescriptions. Early initiation, the authors emphasize, matters far more than the specific choice of substance, since open-label extension data consistently show that patients who started therapy late never regained the survival advantage of those treated from the beginning.

For patients in whom therapy is already underway, the consensus defines multimodal criteria for recognizing disease progression, including heart failure hospitalization, diuretic intensification, NT-proBNP increases above 700 picograms per milliliter with a relative rise exceeding 30 percent, eGFR declines greater than 20 percent, worsening quality of life scores, or NYHA class deterioration. Fulfillment of at least two criteria after 12 months of adequate therapy, without another identifiable cause, may prompt consideration of switching substance or class, although the panel acknowledges that prospective data to guide such switches do not yet exist. As a rule of thumb, specific therapy requires two to three years to deliver significant prognostic benefit, meaning patients with a life expectancy under two years are unlikely to benefit and should instead receive optimal supportive care. The panel also cautions against combination therapy, which appears safe but lacks randomized evidence of incremental efficacy, and points to a rich pipeline of future options, including the antisense oligonucleotide eplontersen, the NSAID-derived stabilizer diflunisal, CRISPR-Cas9 gene editing with nexiguran ziclumeran, and amyloid-depleting antibodies such as NI006, which in early trials demonstrated actual removal of cardiac amyloid deposits. For a disease once written off as untreatable, the consensus marks less an endpoint than a beginning.

Subject of Research: Expert consensus recommendations for disease-modifying drug treatment of transthyretin amyloid cardiomyopathy in Germany

Article Title: Specific treatment of ATTR-CM in Germany—expert consensus of the German Society of Amyloid Diseases (DGAK) and German Cardiac Society (DGK)

Article References: aus dem Siepen, F., Trenkwalder, T., Aßmus, B., Kindermann, I., Lavall, D., Spethmann, S., Michel, L., Hansen, T., Kruck, S., Rischpler, C., Knebel, F., Schwarting, S. K., Bavendiek, U., Papathanasiou, M., Hegenbart, U., Yilmaz, A., Hahn, K., Carpinteiro, A., Pfister, R., & Morbach, C. (2026). Specific treatment of ATTR-CM in Germany—expert consensus of the German Society of Amyloid Diseases (DGAK) and German Cardiac Society (DGK). Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-03006-1

Image Credits: AI Generated

DOI: 10.1007/s00392-026-03006-1

Keywords: ATTR-CM, transthyretin amyloid cardiomyopathy, tafamidis, acoramidis, vutrisiran, amyloidosis, heart failure, TTR stabilizers, gene silencing, DGAK, DGK, expert consensus